Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin

PLoS Neglected Tropical Diseases

Volumn 1, Issue 1, 2007, Pages

  Schütte, Daniela ^a   Um Boock, Alphonse ^b   Mensah Quainoo, Ernestina ^c   Itin, Peter ^d   Schmid, Peter ^e   Pluschke, Gerd ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Leprosy Relief Emmaus Switzerland (ALES) Cameroon   (Cameroon)

^c GHANA HEALTH SERVICE   (Ghana)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BURULI ULCER; CELL AGGREGATION; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GRANULOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; MONONUCLEAR PHAGOCYTE; MYCOBACTERIUM; OBSERVATIONAL STUDY; TREATMENT DURATION; DRUG EFFECT; GHANA; ISOLATION AND PURIFICATION; LYMPHOCYTE; MICROBIOLOGY; MYCOBACTERIOSIS; PATHOLOGY;

ANTI-BACTERIAL AGENTS; BURULI ULCER; CHILD; GHANA; GRANULOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RIFAMPIN; STREPTOMYCIN;

EID: 47749152972     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000002     Document Type: Article

References (43)

1. Asiedu A, Scherpbier RW, Raviglione M (2000) Buruli ulcer, Mycobacterium ulcer infection. World Health Organization: Geneva, Switzerland.
2. Johnson PD, Stinear TP, Small PL, Pluschke G, Merritt RW, et al. (2005) Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2: e108.
3. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
4. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 101: 1345-1349.
5. Snyder D, Small PL (2003) Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 34: 91-101.
6. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 1295-1304.
7. George KM, Barker LP, Welty DM, Small PL (1998) Partial purification and characterization ofb iological effects of a lipid toxin produced by Mycobacterium ulcerans. InfectImmun 66: 587-593.
8. Thangaraj HS, Evans MR, Wansbrough-Jones MH (1999) Mycobacterium ulcerans disease; Buruli ulcer. Trans R Soc Trop Med Hyg 93: 337-340.
9. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, et al. (2005) Mycobacterium ulcerans disease. Bull World Health Organ 83: 785-791.
10. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. (2004) Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 10: 1391-1398.
11. Marsollier L, Stinear T, Aubry J, Saint Andre JP, Robert R, et al. (2004) Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment. Appl Environ Microbiol 70: 1097-1103.
12. Marsollier L, Robert R, Aubry J, Saint Andre JP, Kouakou H, et al. (2002) Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 68: 4623-4628.
13. Marsollier L, Severin T, Aubry J, Meritt RW, Saint Andre JP, et al. (2004) Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol 70: 6296-6298.
14. Marsollier L, AubryJ, Coutanceaur E, Andre JP, Small PL, Milon G, et al. (2005) Colonization of the salivary glands of Naucoris cimicoides by Mycobacterium ulcerans requires host plasmatocytes and a macrolide toxin, mycolactone. Cell Microbiol 7: 935-943.
15. Carey MJ, Connor DH (1997) Buruli ulcer - infection with Mycobacterium ulcerans. In Pathology of infectious diseases Appleton & Lange: Stamford (CT). pp 453-459.
16. Buntine J, Crofts K (2001) Management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization: Geneva, Switzerland. pp 28-40.
17. Sizaire V, Nackers F, Comte E, Portaels F (2006) Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 6: 288-296.
18. Rondin S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas 8, et al. (2006) Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 208: 119-128.
19. World Health Organization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer) World Health Organization: Geneva, Switzerland.
20. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182-3186.
21. Chauty A (2005) Treatment of Buruli ulcer with the combination of Rifampicin and Streptomycin in Benin In: 8th WHO advisory group meeting on Buruli ulcer; 2005 14-17 March; World Health Organization: Geneva, Switzerland.
22. Hayman J, Mcqueen A (1985) The Pathology or Mycobacterium Ulcerans Infection. Pathology 17: 594-600.
23. Hayman J (1993) Out of Africa-Observations on the Histopathology or Mycobacterium-Ulecrans Infection. Journal of Clinical Pathology 46: 5-9.
24. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, et al. (2003) Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 9: 651-656.
25. Kiszewski AE, Becerril E, Aguilar LD, Kader IT, Myers W, et al. (2006) The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 143: 445-451.
26. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
27. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73: 6299-6310.
28. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7: 1187-1196.
29. Drayton DL, Liao S, Mounzer RH, Ruddle NH (2006) Lymphoid organ development: from ontogeny to neogenesis. Nature Immunology 7: 344-353.
30. Gregory CD, Devitt A (1999) CD14 and apoptosis. Apoptosis 4: 11-20.
31. Gimenez MF, Gigli I, Tausk FA (1989) Differential Expression of Langerhans Cells in the Epidermis of Patients with Leprosy. British Journal of Dermatology 121: 19-26.
32. Dannenberg AM (1991) Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 12: 228-233.
33. Narayanan RB (1988) Immunopathology of Leprosy Granulomas-Current Staturs-A Review. Leprosy Review 59: 75-82.
34. Mukherjee A, Misra RS (1988) Comparative Histology of Skin and Nerve Granulomas in Leprosy Patients. Leprosy Review 59: 177-180.
35. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, et al. (2004) Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate locad host defence in the lung. J Pathol 204: 217-228.
36. Peduzzi E, Groeper C, Schutte D, Zajac P, Rondini S, et al. (2006) Local Activation of the Innate Immune System in Buruli Ulcer Lesions. J Invest Dermatol.
37. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2006) Evidence for an Intramacrophage Growth Phase of Mycobacterium ulcerans. Infect Immun.
38. Ulrichs T, Lefmann M, Reich M, Morawietz L, Roth A, et al. (2005) Modified immunohistological staining allows detection of ZichI-Neelsen-negative Mycobacterium tuberculosis organisms and their precise localization in human tissue. J Pathol 205: 633-640.
39. Rondini S, Mensah-Quainoo E, Troll H, Bodmer T, Pluschke G (2003) Development and application of real-time PCR assay for quantification of Mycobacterium ulcerans DNA. J Clin Microbiol 41: 4231-4237.
40. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, et al. (2004) Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364: 2113-2121.
41. Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, et al. (2005) Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 115: 2480-2488.
42. Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, et al. (2006) Use of the immunodommant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 13: 1314-1321.
43. Mwanatambwe M, Fukunishi Y, Yajima M, Suzuki K, Asiedu K, et al. (2000) Clinico-histopathological findings of Buruli ulcer. Nihon Hansenbyo Gakkai Zasshi 69: 93-100.